Woodline Partners LP Raises Stock Holdings in argenx SE (NASDAQ:ARGX)

Woodline Partners LP boosted its holdings in shares of argenx SE (NASDAQ:ARGX - Free Report) by 299.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 74,237 shares of the company's stock after acquiring an additional 55,656 shares during the quarter. Woodline Partners LP owned 0.12% of argenx worth $45,656,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of ARGX. Point72 Europe London LLP purchased a new stake in shares of argenx during the fourth quarter valued at $5,839,000. Stephens Inc. AR bought a new stake in argenx during the 4th quarter valued at about $310,000. Ritholtz Wealth Management boosted its position in argenx by 85.5% in the 4th quarter. Ritholtz Wealth Management now owns 898 shares of the company's stock valued at $552,000 after buying an additional 414 shares during the period. Jones Financial Companies Lllp grew its stake in argenx by 1,016.7% in the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock worth $41,000 after acquiring an additional 61 shares in the last quarter. Finally, Park Avenue Securities LLC increased its position in shares of argenx by 40.0% during the fourth quarter. Park Avenue Securities LLC now owns 1,695 shares of the company's stock worth $1,042,000 after acquiring an additional 484 shares during the period. Institutional investors own 60.32% of the company's stock.

Analyst Upgrades and Downgrades

ARGX has been the topic of several research analyst reports. Wells Fargo & Company increased their price objective on argenx from $723.00 to $741.00 and gave the stock an "overweight" rating in a research note on Friday, February 28th. HC Wainwright reissued a "buy" rating and set a $720.00 price target on shares of argenx in a research report on Tuesday, April 8th. Oppenheimer lifted their price objective on argenx from $704.00 to $708.00 and gave the company an "outperform" rating in a report on Friday, May 9th. Sanford C. Bernstein raised shares of argenx from a "market perform" rating to an "outperform" rating in a research report on Monday, March 17th. Finally, Guggenheim reduced their price target on shares of argenx from $1,100.00 to $1,065.00 and set a "buy" rating for the company in a report on Friday, May 9th. One investment analyst has rated the stock with a hold rating, twenty have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, argenx has an average rating of "Buy" and a consensus price target of $698.11.

argenx Price Performance

Shares of ARGX stock opened at $578.10 on Tuesday. argenx SE has a 1-year low of $356.38 and a 1-year high of $678.21. The company has a market cap of $35.30 billion, a price-to-earnings ratio of -656.93 and a beta of 0.57. The stock has a 50 day simple moving average of $591.36 and a 200-day simple moving average of $613.42.

argenx (NASDAQ:ARGX - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $2.58 earnings per share for the quarter, topping analysts' consensus estimates of $2.32 by $0.26. The company had revenue of $1.35 billion during the quarter, compared to analysts' expectations of $748.34 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. Analysts anticipate that argenx SE will post 3.13 earnings per share for the current fiscal year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.

Want to see what other hedge funds are holding ARGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for argenx SE (NASDAQ:ARGX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.